Toshiko Nakai
Overview
Explore the profile of Toshiko Nakai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
139
Citations
997
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ikeya Y, Okumura Y, Kogawa R, Nagashima K, Nakai T, Yokoyama K, et al.
J Arrhythm
. 2024 Jun;
40(3):423-433.
PMID: 38939793
Background: Despite the positive impact of implantable cardioverter defibrillators (ICDs) and wearable cardioverter defibrillators (WCDs) on prognosis, their implantation is often withheld especially in Japanese heart failure patients with reduced...
2.
3.
Otsuka N, Okumura Y, Kuorkawa S, Nagashima K, Wakamatsu Y, Hayashida S, et al.
J Cardiovasc Electrophysiol
. 2023 Oct;
35(1):7-15.
PMID: 37794818
Introduction: High-power short-duration (HPSD) ablation at 50 W, guided by ablation index (AI) or lesion size index (LSI), and a 90 W/4 s very HSPD (vHPSD) setting are available for...
4.
Mano H, Nakai T, Ikeya Y, Kogawa R, Saito Y, Kurokawa S, et al.
Int Heart J
. 2023 May;
64(3):358-364.
PMID: 37197920
One benefit of an implantable cardioverter-defibrillator is the prevention of sudden cardiac death (SCD). It is recommended for patients with a low left ventricular ejection fraction (LVEF). However, the choice...
5.
Otsuka N, Okumura Y, Kuorkawa S, Nagashima K, Wakamatsu Y, Hayashida S, et al.
J Cardiovasc Electrophysiol
. 2022 Dec;
34(2):369-378.
PMID: 36527433
Introduction: Neither the actual in vivo tissue temperatures reached with 90 W/4 s-very high-power short-duration (vHPSD) ablation for atrial fibrillation nor the safety and efficacy profile have been fully elucidated....
6.
Otsuka N, Okumura Y, Kuorkawa S, Nagashima K, Wakamatsu Y, Hayashida S, et al.
J Cardiovasc Electrophysiol
. 2022 Oct;
34(1):108-116.
PMID: 36300696
Background: Neither the actual in vivo tissue temperatures reached with lesion size index (LSI)-guided high-power short-duration (HPSD) ablation for atrial fibrillation nor the safety profile has been elucidated. Methods: We...
7.
Sasa Y, Nakai T, Ikeya Y, Kogawa R, Otsuka N, Kurokawa S, et al.
Int Heart J
. 2022 Mar;
63(2):393-397.
PMID: 35296616
Sleep apnea syndrome (SAS) is a condition in which apnea and hypoventilation at night cause hypoxemia and impaired wakefulness during the day, resulting in a general malaise and dozing. Sleep...
8.
Aizawa Y, Nakai T, Ikeya Y, Kogawa R, Saito Y, Toyama K, et al.
Heart Vessels
. 2022 Feb;
37(8):1411-1417.
PMID: 35133499
Some patients with pacemakers present with first-degree atrioventricular (AV) block. To avoid right ventricular (RV) pacing, preserving intrinsic AV conduction as much as possible is recommended. However, there is no...
9.
Saito Y, Nakai T, Ikeya Y, Kogawa R, Otsuka N, Wakamatsu Y, et al.
Heart Vessels
. 2022 Jan;
37(7):1136-1145.
PMID: 35066673
Despite emerging recognition of interactions between heart failure (HF) and liver dysfunction, the impact of cardiac hepatopathy on patients with HF undergoing cardiac resynchronization therapy (CRT) has not been fully...
10.
Saito Y, Nakai T, Ikeya Y, Kogawa R, Otsuka N, Wakamatsu Y, et al.
ESC Heart Fail
. 2022 Jan;
9(2):1080-1089.
PMID: 34983080
Aims: Multi-organ dysfunction was recently reported to be a common condition in patients with heart failure (HF). The Model for End-stage Liver Disease eXcluding International normalized ratio (MELD-XI) score reflects...